vs
BALCHEM CORP（BCPC）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
BALCHEM CORP的季度营收约是REPLIGEN CORP的1.4倍（$270.7M vs $197.9M），BALCHEM CORP净利率更高（14.9% vs 6.7%，领先8.2%），REPLIGEN CORP同比增速更快（13.6% vs 8.1%），BALCHEM CORP自由现金流更多（$33.8M vs $17.6M），过去两年REPLIGEN CORP的营收复合增速更高（14.4% vs 7.5%）
Balchem Corp是一家全球特种化学品与营养原料供应商，核心业务覆盖人类营养、动物保健、制药、工业应用四大领域，为北美、欧洲、亚太等地区的客户提供定制化专用原料产品。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
BCPC vs RGEN — 直观对比
营收规模更大
BCPC
是对方的1.4倍
$197.9M
营收增速更快
RGEN
高出5.6%
8.1%
净利率更高
BCPC
高出8.2%
6.7%
自由现金流更多
BCPC
多$16.3M
$17.6M
两年增速更快
RGEN
近两年复合增速
7.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $270.7M | $197.9M |
| 净利润 | $40.3M | $13.3M |
| 毛利率 | — | 52.5% |
| 营业利润率 | 20.5% | 9.0% |
| 净利率 | 14.9% | 6.7% |
| 营收同比 | 8.1% | 13.6% |
| 净利润同比 | 8.7% | 143.9% |
| 每股收益（稀释后） | $1.25 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BCPCRGEN
| Q1 26 | $270.7M | — | ||
| Q4 25 | $263.6M | $197.9M | ||
| Q3 25 | $267.6M | $188.8M | ||
| Q2 25 | $255.5M | $182.4M | ||
| Q1 25 | $250.5M | $169.2M | ||
| Q4 24 | $240.0M | $174.1M | ||
| Q3 24 | $239.9M | $154.9M | ||
| Q2 24 | $234.1M | $154.1M |
净利润BCPCRGEN
| Q1 26 | $40.3M | — | ||
| Q4 25 | $39.2M | $13.3M | ||
| Q3 25 | $40.3M | $14.9M | ||
| Q2 25 | $38.3M | $14.9M | ||
| Q1 25 | $37.1M | $5.8M | ||
| Q4 24 | $33.6M | $-30.3M | ||
| Q3 24 | $33.8M | $-654.0K | ||
| Q2 24 | $32.1M | $3.3M |
毛利率BCPCRGEN
| Q1 26 | — | — | ||
| Q4 25 | 35.6% | 52.5% | ||
| Q3 25 | 35.7% | 53.2% | ||
| Q2 25 | 36.4% | 50.0% | ||
| Q1 25 | 35.2% | 53.6% | ||
| Q4 24 | 36.0% | 26.1% | ||
| Q3 24 | 35.6% | 50.0% | ||
| Q2 24 | 35.5% | 49.8% |
营业利润率BCPCRGEN
| Q1 26 | 20.5% | — | ||
| Q4 25 | 19.8% | 9.0% | ||
| Q3 25 | 20.4% | 8.9% | ||
| Q2 25 | 20.1% | 7.6% | ||
| Q1 25 | 20.4% | 3.9% | ||
| Q4 24 | 19.8% | -17.7% | ||
| Q3 24 | 20.0% | -5.1% | ||
| Q2 24 | 19.6% | 1.0% |
净利率BCPCRGEN
| Q1 26 | 14.9% | — | ||
| Q4 25 | 14.9% | 6.7% | ||
| Q3 25 | 15.1% | 7.9% | ||
| Q2 25 | 15.0% | 8.2% | ||
| Q1 25 | 14.8% | 3.4% | ||
| Q4 24 | 14.0% | -17.4% | ||
| Q3 24 | 14.1% | -0.4% | ||
| Q2 24 | 13.7% | 2.2% |
每股收益（稀释后）BCPCRGEN
| Q1 26 | $1.25 | — | ||
| Q4 25 | $1.21 | $0.24 | ||
| Q3 25 | $1.24 | $0.26 | ||
| Q2 25 | $1.17 | $0.26 | ||
| Q1 25 | $1.13 | $0.10 | ||
| Q4 24 | $1.03 | $-0.55 | ||
| Q3 24 | $1.03 | $-0.01 | ||
| Q2 24 | $0.98 | $0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $72.9M | $767.6M |
| 总债务越低越好 | — | $542.2M |
| 股东权益账面价值 | $1.3B | $2.1B |
| 总资产 | $1.7B | $2.9B |
| 负债/权益比越低杠杆越低 | — | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资BCPCRGEN
| Q1 26 | $72.9M | — | ||
| Q4 25 | $74.6M | $767.6M | ||
| Q3 25 | $65.1M | $748.7M | ||
| Q2 25 | $65.4M | $708.9M | ||
| Q1 25 | $49.9M | $697.2M | ||
| Q4 24 | $49.5M | $757.4M | ||
| Q3 24 | $73.7M | $784.0M | ||
| Q2 24 | $63.7M | $809.1M |
总债务BCPCRGEN
| Q1 26 | — | — | ||
| Q4 25 | — | $542.2M | ||
| Q3 25 | — | $537.9M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $525.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益BCPCRGEN
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $2.1B | ||
| Q3 25 | $1.3B | $2.1B | ||
| Q2 25 | $1.3B | $2.1B | ||
| Q1 25 | $1.2B | $2.0B | ||
| Q4 24 | $1.1B | $2.0B | ||
| Q3 24 | $1.2B | $2.0B | ||
| Q2 24 | $1.1B | $2.0B |
总资产BCPCRGEN
| Q1 26 | $1.7B | — | ||
| Q4 25 | $1.7B | $2.9B | ||
| Q3 25 | $1.7B | $2.9B | ||
| Q2 25 | $1.7B | $2.9B | ||
| Q1 25 | $1.6B | $2.9B | ||
| Q4 24 | $1.6B | $2.8B | ||
| Q3 24 | $1.6B | $2.8B | ||
| Q2 24 | $1.6B | $2.9B |
负债/权益比BCPCRGEN
| Q1 26 | — | — | ||
| Q4 25 | — | 0.26× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.27× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $40.1M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | $33.8M | $17.6M |
| 自由现金流率自由现金流/营收 | 12.5% | 8.9% |
| 资本支出强度资本支出/营收 | 2.3% | 4.1% |
| 现金转化率经营现金流/净利润 | 0.99× | 1.93× |
| 过去12个月自由现金流最近4个季度 | — | $93.9M |
8季度趋势，按日历期对齐
经营现金流BCPCRGEN
| Q1 26 | $40.1M | — | ||
| Q4 25 | $67.3M | $25.7M | ||
| Q3 25 | $65.6M | $48.1M | ||
| Q2 25 | $47.3M | $28.6M | ||
| Q1 25 | $36.5M | $15.0M | ||
| Q4 24 | $52.3M | $39.2M | ||
| Q3 24 | $51.3M | $49.3M | ||
| Q2 24 | $45.0M | $42.2M |
自由现金流BCPCRGEN
| Q1 26 | $33.8M | — | ||
| Q4 25 | — | $17.6M | ||
| Q3 25 | — | $43.4M | ||
| Q2 25 | — | $21.5M | ||
| Q1 25 | — | $11.4M | ||
| Q4 24 | — | $33.6M | ||
| Q3 24 | — | $42.3M | ||
| Q2 24 | — | $37.4M |
自由现金流率BCPCRGEN
| Q1 26 | 12.5% | — | ||
| Q4 25 | — | 8.9% | ||
| Q3 25 | — | 23.0% | ||
| Q2 25 | — | 11.8% | ||
| Q1 25 | — | 6.8% | ||
| Q4 24 | — | 19.3% | ||
| Q3 24 | — | 27.3% | ||
| Q2 24 | — | 24.3% |
资本支出强度BCPCRGEN
| Q1 26 | 2.3% | — | ||
| Q4 25 | — | 4.1% | ||
| Q3 25 | — | 2.5% | ||
| Q2 25 | — | 3.9% | ||
| Q1 25 | — | 2.1% | ||
| Q4 24 | — | 3.2% | ||
| Q3 24 | — | 4.5% | ||
| Q2 24 | — | 3.1% |
现金转化率BCPCRGEN
| Q1 26 | 0.99× | — | ||
| Q4 25 | 1.72× | 1.93× | ||
| Q3 25 | 1.63× | 3.23× | ||
| Q2 25 | 1.23× | 1.92× | ||
| Q1 25 | 0.98× | 2.57× | ||
| Q4 24 | 1.56× | — | ||
| Q3 24 | 1.52× | — | ||
| Q2 24 | 1.40× | 12.70× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
